Genetically modified bacillus subtilis strain and use as a live delivery and production system
AssigneeBiomEdit, Inc.
InventorsDharanesh Mahimapura Gangaiah, Arvind Kumar, Shrinivasrao Peerajirao Mane
Life of this patent
Estimating the term…
Abstract
The present invention relates to genetically modified Bacillus subtilis, compositions, and uses thereof in production of biomolecules and heterologous proteins and for delivery of biomolecules and heterologous proteins in animals and associated methods for improving animal health.
Claims70
A modified Bacillus bacteria for production or live delivery of one or more biomolecule or heterologous protein, wherein the bacteria comprises Bacillus subtilis strain 105 (ELA191105) genetically modified in one or more aspect selected from the following:
- (a) genetically modified to increase competency;
- (b) genetically modified to reduce or block spore formation;
- (c) genetically modified to delete or inactivate one or more native protease;
- and
- (d) genetically modified to include nucleic acid encoding one or more biomolecule or heterologous protein;
- wherein the B subtilis strain 105 comprises the nucleic acid sequence set out in SEO ID NO:
- 1, 2, 3, 4, 5 or 6 or comprises nucleic acid that has at least 90% identity, 95% identity, 97% identity, 98% identity, 99% identity in genomic sequence to SEO ID NO:
- 1, 2, 3, 4 5 or 6, or
- wherein the Bacillus subtilis strain corresponds to ATCC deposit PTA-126786 strain or has at least 95% identity, 97% identity, 98% identity, 99% identity in genomic sequence to the sequence of ELA191105 corresponding to ATCC deposit PTA-126786.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A live delivery platform comprising a genetically-modified Bacillus bacteria for production of one or more biomolecules or heterologous proteins in an animal, wherein the modified Bacillus comprises Bacillus subtilis strain 105 (ELA191105) genetically modified to include nucleic acid encoding one or more biomolecule or heterologous protein which is produced and delivered upon administration of the modified Bacillus bacteria to the animal, wherein the bacteria comprises Bacillus subtilis strain 105 (ELA191105) genetically modified in one or more aspect selected from the following:
- (a) genetically modified to increase competency:
- (b) genetically modified to reduce or block spore formation:
- (c) genetically modified to delete or inactivate one or more native protease;
- and
- (d) genetically modified to include nucleic acid encoding one or more biomolecule or heterologous protein:
- wherein the Bacillus subtilis strain 105 comprises the nucleic acid sequence set out in SEQ ID NO:
- 1 or comprises at least 95% identity, 97% identity, 98% identity, 99% identity in genomic sequence to SEO ID NO:
- 1, or
- wherein the Bacillus subtilis strain corresponds to ATCC deposit PTA-126786 strain or has at least 95% identity, 97% identity, 98% identity, 99% identity in genomic sequence to the sequence of ELA191105 corresponding to ATCC deposit PTA-126786.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.